Compare Quantumscape Corp (QS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs ResMed Inc. — how do they compare? Quantumscape Corp trades at $4.54 (market cap $2.82B), while ResMed Inc. trades at $229.72 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 11.3× Quantumscape Corp's market cap, and ResMed Inc. pays a 1.16% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and ResMed Inc. for 51 Days on average.
| QS | RMD | |
|---|---|---|
Market Cap | $2.82B | $31.89B |
Volume | 21,878,246 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $277.88 |
52-Week Low | $4.52 | $182.82 |
Typical Hold Time | 37 Days | 51 Days |
Enterprise Value | $2.03B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.545, up 0.55% on the day, but remains in a bearish technical trend with significant fundamental challenges. The company continues to operate without revenue while reporting substantial losses (-$435.05M net income in 2025). Recent earnings show mixed results with two beats and one miss in the last four quarters. The stock faces headwinds from delayed commercialization timelines and insider selling activity, though institutional interest persists with Bank of New York Mellon establishing a new position.
QS represents a high-risk, speculative investment opportunity in solid-state battery technology. The primary opportunity lies in potential commercialization success with automotive partners like Volkswagen, while major risks include continued cash burn, competitive threats, and execution delays. Analyst consensus remains cautious with 73% hold ratings and a $10.35 price target suggesting 128% upside from current levels, but the path to profitability remains uncertain.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
